Claire E. Dearden, MD, Highlights the Pharmacotherapeutic Strategies for the Management of B- and T-cell PLL

Article

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

This video was taken on Saturday, December 8, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Stephanie Tagliatela on Researching AAV for Lennox-Gastaut, Alzheimer Disease, SCN9a Pain
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Jacques Galipeau, MD, on Working to Streamline Cell and Gene Therapy Development
Related Content
Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024

Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024

Noah Stansfield
July 24th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Haydar Frangoul, MD, Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial

Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy

Victoria Johnson
July 24th 2024
Article

Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.

Silviu Itescu, MBBS, FRACP, chief Executive Officer and Managing Director, Mesoblast

FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD

Victoria Johnson
July 23rd 2024
Article

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences

Caribou Biosciences chRDNA Technology Provides a Unique Approach to CRISPR-Based Gene Editing

Noah Stansfield
July 23rd 2024
Article

Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences, discussed the company’s platform for genome editing.

Ash Alizadeh, MD, PhD, professor of medicine and member, Stanford Cancer Institute

Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T

Victoria Johnson
July 22nd 2024
Article

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel

Noah Stansfield
July 22nd 2024
Article

In honor of World Brain Day, observed annually on July 22 by patient and clinician communities, CGTLive is taking a closer look at this ongoing study.

© 2024 MJH Life Sciences

All rights reserved.